Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Change in Receivables (2016 - 2025)

Tvardi Therapeutics' Change in Receivables history spans 11 years, with the latest figure at $822000.0 for Q1 2025.

  • On a quarterly basis, Change in Receivables rose 178.51% to $822000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was -$489000.0, a 68.27% increase, with the full-year FY2024 number at -$2.4 million, down 376.36% from a year prior.
  • Change in Receivables hit $822000.0 in Q1 2025 for Tvardi Therapeutics, up from -$28000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for TVRD hit a ceiling of $20.0 million in Q3 2021 and a floor of -$19.9 million in Q4 2021.
  • Historically, Change in Receivables has averaged -$123058.8 across 5 years, with a median of -$28000.0 in 2024.
  • Biggest five-year swings in Change in Receivables: soared 83620.83% in 2021 and later plummeted 104600.0% in 2024.
  • Tracing TVRD's Change in Receivables over 5 years: stood at -$19.9 million in 2021, then soared by 51.84% to -$9.6 million in 2022, then surged by 82.46% to -$1.7 million in 2023, then soared by 98.33% to -$28000.0 in 2024, then skyrocketed by 3035.71% to $822000.0 in 2025.
  • Business Quant data shows Change in Receivables for TVRD at $822000.0 in Q1 2025, -$28000.0 in Q4 2024, and -$2.5 million in Q3 2024.